After Seaport Global and Maxim Group gave Omeros Corp (NASDAQ: OMER) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp today and set a price target of $34. The company’s shares closed on Friday at $21.80.
Selvaraju wrote:
“Valuation methodology, risks and uncertainties. We ascribe a total firm value of roughly $2B to Omeros based on OMIDRIA ($806M) and OMS721 ($1.18B). This translates into a target of $34.00 per share, based on 58M fully-diluted shares outstanding as of end-1Q 2019.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -4.8% and a 33.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is a Strong Buy with an average price target of $27.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.20 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 823.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
